Chemistry:Sepetaprost
From HandWiki
Sepetaprost is an investigational new drug that is being evaluated for the treatment of open angle glaucoma and ocular hypertension.[1] It is an agonist of the prostaglandin EP3 and F receptors.[2]
As of 2025 Sepetaprost is registered in Japan as Setaneo[3] ophthalmic solution 0.002%, sold by Santen Pharmaceuticals. It is indicated for the treatment of glaucoma and ocular hypertension.
References
- ↑ "Sepetaprost - Santen Pharmaceutical". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800035556.
- ↑ "FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma". Experimental Eye Research 229. April 2023. doi:10.1016/j.exer.2023.109415. PMID 36803996.
- ↑ "Santen Launches SETANEO®". https://www.santen.com/en/news/2025/2025_1/20251023.
 |  |
